1. A transdermal pharmaceutical composition comprising a type 5 phosphodiesterase inhibitor (PDE-5) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, characterized in that the composition further comprises an enhancer selected from the group consisting of cocamidopropyl betaine, sodium lauroamphoacetate, quaternium-60 , isostearamidopropyl morpholine lactate, dipropylene glycol and a combination thereof； wherein the PDE-5 inhibitor and enhancer are present in the transdermal pharmaceutical composition in a ratio of from about 20: 1 to 2: 1.2. A composition according to claim 1, characterized in that the PDE-5 inhibitor is any of sildenafil, tadalafil or vardenafil. A composition according to claim 2, wherein the PDE-5 inhibitor is vardenafil. The composition of claim 2, wherein the PDE-5 inhibitor and enhancer are present in a ratio of about 5: 1.5. A composition according to claim 2, characterized in that the PDE-5 inhibitor is not in a crystalline state. A method for accelerating the transdermal delivery of a type 5 phosphodiesterase inhibitor (PDE-5) in a subject, the method comprising administering to the subject a transdermal pharmaceutical composition according to claim 1.7. The method of claim 6, wherein the PDE-5 inhibitor is any of sildenafil, tadalafil, or vardenafil. The method of claim 7, wherein the PDE-5 inhibitor is vardenafil. The method of claim 7, wherein the PDE-5 inhibitor and amplifier are used in a ratio of about 5: 1.10. The method of claim 6, wherein the PDE-5 inhibitor is not in a crystalline state.1. Трансдермальная фармацевтическая композиция, содержащая ингибитор фосфодиэстеразы 5-го типа (PDE-5) или его фармацевтически приемлемую соль и фармацевтически приемлемый наполнитель, отличающаяся тем, что композиция дополнительно содержит усилитель, выбранный из группы, включающей кокамидопропилбетаин, лауроамфоацетат натрия, кватерний-60, изостеарамидопропил морфолина лактат, дипропиленгликоль и их комби
